Ascendis Pharma initiates TransCon Treprostinil Stage 1 research in healthy volunteers Ascendis Pharma A/S, a clinical stage biotechnology company that applies its innovative TransCon technology to address significant unmet medical requirements, today announced that it has initiated a Stage 1 single ascending dose research of TransCon Treprostinil in healthy volunteers. TransCon Treprostinil has been developed to treat pulmonary arterial hypertension, a life-threatening orphan disease seen as a elevated blood circulation pressure in the pulmonary arteries. TransCon Treprostinil has been designed as an inert prodrug that enables a sustained launch of unmodified treprostinil in circulation following a once-daily self-administered subcutaneous injection ejaculation over 50 .
The study was published in the November problem of Developmental Psychology. MORE Wellness CONTENT FROM CBS NEWS: Tyler Clementi: Rutgers Suicide Freshman kills personal after video of him with another guy appears online, say law enforcement BPA: 7 secret sources From wc paper to your son or daughter’s mouth, you’ll be shocked.. Asher Brown Suicide: Was Bullying at fault? Is lifestyle really harder for gay teens and various other young people who don’t confirm to gender norms? Certainly, a new research says. It showed that the mental health of lesbian, gay, bisexual and transgender teenagers is normally severely compromised by bullying and harassment they receive in school. The scholarly study comes on the heels of the suicides of Asher Dark brown, a 13-year-previous in Houston who fatally shot himself after his classmates reportedly produced fun of him because they thought he was gay, and of Tyler Clementi, a Rutgers University pupil who killed himself after another college student posted video on the web of him making out with a man.